Evolving Treatment Landscape in Relapsed/Refractory Multiple Myeloma

The discussion opens with an overview of the rapidly evolving treatment landscape in relapsed/refractory multiple myeloma, highlighting the expanding range of BCMA-directed therapeutic approaches. Dr. Hans Lee introduces the panel and frames the discussion around BCMA-directed bispecific antibodies, antibody-drug conjugates, CAR T-cell therapy, and emerging treatment strategies. Dr. Paul Richardson reflects on the major advances in multiple myeloma over the past decade, including the transition of immunomodulatory agents, proteasome inhibitors, and CD38-directed monoclonal antibodies into earlier lines of therapy and the increasing use of quadruplet regimens. He discusses how these advances have improved progression-free survival and allowed clinicians to consider reserving transplant for selected patients. Dr. Richardson then highlights the growing number of BCMA-targeted modalities, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates, emphasizing the importance of treatment sequencing. The discussion also underscores the heterogeneity of patients with relapsed/refractory multiple myeloma and the need to tailor treatment according to individual patient needs, preferences, and treatment-related toxicities.